U.S. markets closed
  • S&P 500

    3,269.96
    -40.15 (-1.21%)
     
  • Dow 30

    26,501.60
    -157.51 (-0.59%)
     
  • Nasdaq

    10,911.59
    -274.00 (-2.45%)
     
  • Russell 2000

    1,538.48
    -23.10 (-1.48%)
     
  • Crude Oil

    35.72
    -0.45 (-1.24%)
     
  • Gold

    1,878.80
    +10.80 (+0.58%)
     
  • Silver

    23.72
    +0.35 (+1.52%)
     
  • EUR/USD

    1.1650
    -0.0029 (-0.24%)
     
  • 10-Yr Bond

    0.8600
    +0.0250 (+2.99%)
     
  • GBP/USD

    1.2951
    +0.0028 (+0.22%)
     
  • USD/JPY

    104.6620
    +0.0520 (+0.05%)
     
  • BTC-USD

    13,579.58
    +32.59 (+0.24%)
     
  • CMC Crypto 200

    265.42
    +1.78 (+0.68%)
     
  • FTSE 100

    5,577.27
    -4.48 (-0.08%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PROG, ODT and BMRN

·3 mins read

NEW YORK, NY / ACCESSWIRE / October 12, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Progenity, Inc. (NASDAQ:PROG)
This lawsuit is on behalf of all purchasers of Progenity common stock pursuant and/or traceable to the registration statement, as amended, issued in connection with Progenity's June 2020 initial public offering.
Lead Plaintiff Deadline: October 27, 2020

The PROG lawsuit alleges that throughout the class period, Progenity, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) that Progenity had overbilled government payors by $10.3 million in 2019 and early 2020 and, thus, had materially overstated its revenues, earnings and cash flows from operations for the historical financial periods provided in the registration statement; (ii) that Progenity would need to refund this overpayment in the second quarter of 2020 (the same quarter in which the initial public offering was conducted), adversely impacting its quarterly results; and (iii) that Progenity was suffering from accelerating negative trends in the second quarter of 2020 with respect to the Company's testing volumes, revenues and product pricing.

Learn about your recoverable losses in PROG: http://www.kleinstocklaw.com/pslra-1/progenity-inc-loss-submission-form?id=10040&from=1

Odonate Therapeutics, Inc. (NASDAQ:ODT)
Class Period: December 7, 2017 - April 21, 2020
Lead Plaintiff Deadline: November 16, 2020

The complaint alleges that throughout the class period Odonate Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ODT: http://www.kleinstocklaw.com/pslra-1/odonate-therapeutics-inc-loss-submission-form?id=10040&from=1

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Class Period: February 28, 2020 - August 18, 2020
Lead Plaintiff Deadline: November 24, 2020

The complaint alleges BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in BMRN: http://www.kleinstocklaw.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?id=10040&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/610203/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-PROG-ODT-and-BMRN